The Urinary Microbiome and Its Relationship to the Urinary and Serum Metabolome in Healthy Peri- and Postmenopausal Women
Launched by UNIVERSITY HOSPITAL OSTRAVA · Aug 23, 2024
Trial Information
Current as of August 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the urinary microbiome, which is the collection of bacteria and other microorganisms in the urine, and how it relates to the levels of certain substances (metabolites) found in urine and blood, specifically in healthy women who are going through or have completed menopause. The goal is to better understand the differences in these microbiomes and metabolomes, which could help in understanding urinary tract infections (UTIs) in women in this age group.
To be eligible for the study, participants must be women over 50 years old, willing to provide urine and blood samples, and able to give their consent to join the study. However, women with certain conditions like recurrent UTIs, urinary tract defects, or other health issues that might affect bladder function will not be able to participate. If you decide to join, you will be asked to provide samples and complete some questionnaires to help researchers gather important information. This study is not yet recruiting, so participants will be contacted once it begins.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women over 50 years old
- • Consent to participate in the study
- • Willingness to take urine and blood samples according to the protocol
- Exclusion Criteria:
- • Known congenital developmental defects of the urinary tract (congenital hydronephrosis, vesicoureteral reflux, renal agenesis, and hypoplasia, multicystic and polycystic kidneys)
- • Recurrent urinary tract infections (more than 3 episodes in the last 12 months)
- • Presence of any lower-urinary tract symptoms (urgency, frequency, incontinence, stranguria, urge to urinate, weak urine stream, the feeling of post-micturition residue)
- • The presence of a foreign body in the urinary tract - urolithiasis, urinary catheter, ureteral stent
- • Acute or chronic diseases with possible influence on lower-urinary tract function
- • Medications with possible influence on lower-urinary tract function
- • Rheumatoid arthritis
- • Diabetes mellitus
About University Hospital Ostrava
University Hospital Ostrava is a leading medical research institution located in Ostrava, Czech Republic, dedicated to advancing healthcare through innovative clinical trials and research initiatives. As a prominent sponsor of clinical studies, the hospital combines cutting-edge medical technology with a commitment to patient-centered care, fostering collaborations among multidisciplinary teams of healthcare professionals and researchers. With a focus on ethical standards and regulatory compliance, University Hospital Ostrava aims to contribute to the development of new therapies and improve treatment outcomes across various medical fields. Its robust research infrastructure and dedication to scientific excellence position it as a key player in the advancement of medical knowledge and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ostrava, Moravian Silesian Region, Czechia
Patients applied
Trial Officials
Jan Krhut, prof.,MD,PhD
Principal Investigator
University Hospital Ostrava
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported